AMG 386: Suspended Phase III enrollment

Amgen suspended enrollment in the double-blind, placebo-controlled Phase III TRINOVA-2 trial evaluating doxorubicin with and without AMG 386 due to supply issues of doxorubicin. The trial planned to enroll about 380 patients. The Phase III TRINOVA-1 trial comparing weekly IV AMG 386 plus paclitaxel vs. placebo plus paclitaxel in about 900 patients is ongoing. Takeda has exclusive Japanese rights to AMG 386 from Amgen. ...